clinical trials/ BE studies for locally acting drugs [Regulatives / Guidelines]

posted by drgunasakaran1  – 2012-01-31 19:42 (5258 d 08:08 ago) – Posting: # 8033
Views: 6,305

Dear Mr.Jegankm,

You need to conduct single dose, two way, cross over invivo study to show bioequivalence for Sulfasalazine Gastro-resistant Tablets 500 mg.
Since, the concentration obtained after the oral administration of Sulfasalazine 500 mg tablets will be too low due to minimal systemic absorption, it is permissible to administer more than one 500 mg tablets (upto four 500 mg tablets) to obtain adequate plasma concentration for the pharmacokinetic analytes (Sulfasalazine, and the metabolites sulfapyridine and 5-Aminosalicylic -ASA) acid (mesalamine) in plasma.

Bioequivalence will be based on Sulfasalazine as well as 5-Aminosalicylic acid.

For Docusate sodium 100mg soft gelatin capsules, it is preferable to conduct a Pharmacodynamic study.

Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
123 visitors (0 registered, 123 guests [including 9 identified bots]).
Forum time: 04:51 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5